Dolichos lablab Linne Extract for NAFLD Triglyceride Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Non-alcoholic fatty liver disease (NAFLD) is a growing health concern in Korea, with limited effective treatments available, and existing remedies do not adequately address the accumulation of triglycerides in liver cells, which can lead to severe liver damage.
Innovation Solution
A health functional food and pharmaceutical composition incorporating an extract of Dolichos lablab Linne, which reduces triglyceride content in liver cells, thereby preventing or ameliorating NAFLD, and can be used in both human and veterinary applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional remedies are used for NAFLD, then general liver support is provided, but triglyceride accumulation in liver cells is not adequately reduced
Solution Approach 1:
The patent extracts and utilizes specific bioactive compounds from Dolichos lablab Linne, particularly lablabine and other saponins, to target triglyceride metabolism in liver cells. This extraction of specific active ingredients from the traditional herbal remedy provides the targeted effect needed to reduce triglyceride accumulation while maintaining the natural source advantage.
Solution Approach 2:
The patent identifies and utilizes specific chemical compounds (lablabine, saponins) from Dolichos lablab Linne that have been shown to alter metabolic parameters in liver cells. These compounds change the biochemical parameters of triglyceride synthesis, storage, and breakdown, thereby reducing triglyceride content in hepatocytes and treating NAFLD effectively.
2Quantity of substance
If Dolichos lablab Linne extract is administered, then triglyceride accumulation is reduced, but potential toxicity to liver and kidney may occur
Solution Approach 1:
The patent utilizes naturally occurring, biodegradable saponins and lablabine from Dolichos lablab Linne as the active therapeutic agents. These natural compounds are metabolized and eliminated by the body, avoiding accumulation and long-term toxicity associated with synthetic drugs. The use of natural, short-lived active ingredients reduces harmful effects on liver and kidney.
Solution Approach 2:
The patent carefully controls the concentration and dosage of lablabine and saponins to achieve therapeutic effects while avoiding toxic thresholds. By optimizing the parameters of active ingredient concentration, the patent maximizes triglyceride-reducing effects while minimizing potential hepatotoxicity and nephrotoxicity, thereby resolving the contradiction between efficacy and safety.
Data Source
AI summary
A health functional food composition and a pharmaceutical composition for preventing or ameliorating a non-alcoholic fatty liver disease include an extract of Dolichos lablab Linne as an active ingredient. The extract of Dolichos lablab Linne, being an active ingredient, effectively reduces accumulation of triglyceride in hepatocarcinoma cell line (HepG2). Therefore, the compositions are used for functional foods and medicines for the prevention or amelioration of non-alcoholic fatty liver.